30 completed. 30 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 30 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 2 | Completed 2 |
Follow Systemic Sclerosis: new trials by email Literature Review of Systemic Sclerosis trials Research Report on Systemic Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis nemolizumab - Systemic Sclerosis | Phase 2 | Completed | Maruho Co., Ltd. | 6 | 2022-04-20 | 2026-02-13 |
| A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis GS-248, Placebo - Systemic Sclerosis | Phase 2 | Completed | Gesynta Pharma AB | 94 | 2020-12-29 | 2024-08-09 |
| Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue) "ACHIM" as solute (10^9 intestinal microbes/ml) - Systemic Sclerosis | Phase 2 | Completed | Oslo University Hospital | 75 | 2020-09-24 | 2022-10-12 |
| Effects of Fractional CO2 Laser Treatment on Vaginal Symptoms and Sexual Dysfunction in Women With Systemic Sclerosis CO2 Vaginal Laser - Systemic Sclerosis, Vulvovaginal Signs and Symptoms | Phase 2 / Phase 3 | Completed | IRCCS San Raffaele | 16 | 2020-05-01 | 2024-01-30 |
| Cold Challenge With C21 in RP C21, Placebo - Raynaud Phenomenon, Systemic Sclerosis | Phase 2 | Completed | Vicore Pharma AB | 20 | 2020-01-03 | 2023-05-18 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis GLPG1690, Placebo - Systemic Sclerosis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 33 | 2019-01-14 | 2021-05-04 |
| Prednisolone in Early Diffuse Systemic Sclerosis Prednisolone 5 mg, Placebo oral capsule; From August 2020 'no additional treatment' - Systemic Sclerosis | Phase 2 | Completed | Prof. Ariane herrick | 35 | 2017-12-21 | 2021-07-30 |
| Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Tofacitinib, Placebo Oral Tablet - Systemic Sclerosis, Scleroderma | Phase 1 / Phase 2 | Completed | University of Michigan | 15 | 2017-09-25 | 2020-05-08 |
| Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis SAR156597, Placebo - Systemic Sclerosis | Phase 2 | Completed | Sanofi | 97 | 2016-12-21 | 2022-03-21 |
| Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis Oral treprostinil - Systemic Sclerosis, Calcinosis | Phase 2 | Completed | Stanford University | 12 | 2016-10-01 | 2021-06-10 |
| Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis Bortezomib, Placebo, Mycophenolate mofetil - Lung Diseases, Interstitial, Systemic Sclerosis | Phase 2 | Completed | Northwestern University | 9 | 2016-03-01 | 2021-08-25 |
| Safety Of Fat Micrografts With Adipose-Derived Stromal Vascular Fraction In Hands Of Patients With Systemic Sclerosis ADSVF application in the right hand - Systemic Sclerosis | Phase 2 | Completed | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 20 | 2015-08-13 | 2020-05-15 |
| Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) Ambrisentan, Placebo - Systemic Sclerosis, Pulmonary Hypertension | Phase 2 | Completed | Heidelberg University | 38 | 2014-07-01 | 2020-04-30 |
| Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Interleukin 2 - Rheumatoid Arthritis, Ankylosing Spondylitis | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 81 | 2014-01-06 | 2021-07-20 |
| Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) Pirfenidone - Systemic Sclerosis | Phase 2 | Completed | Genentech, Inc. | 63 | 2013-10-01 | 2016-08-04 |
| Rituximab in Systemic Sclerosis Rituximab, Placebo (NaCl) - Systemic Sclerosis | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 22 | 2013-04-09 | 2025-11-20 |
| Proof of Biological Activity of SAR100842 in Systemic Sclerosis SAR100842, Placebo (for SAR100842) - Systemic Sclerosis | Phase 2 | Completed | Sanofi | 32 | 2013-01-01 | 2016-03-25 |
| Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis Belimumab, Mycophenolate Mofetil, Placebo Infusion - Systemic Sclerosis | Phase 2 | Completed | Hospital for Special Surgery, New York | 20 | 2012-08-01 | 2022-05-24 |
| An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod) paquinimod - Systemic Sclerosis | Phase 2 | Completed | Active Biotech AB | 9 | 2011-12-01 | 2014-08-27 |
| IL1-TRAP, Rilonacept, in Systemic Sclerosis Rilonacept, Placebo - Scleroderma, Systemic Sclerosis | Phase 1 / Phase 2 | Completed | Boston University | 24 | 2011-12-01 | 2018-05-01 |
Showing 20 of 30. Sign in to see all of them.
Scleroderma, Systemic (30) · Scleroderma, Diffuse (12) · Arthritis (3) · Connective Tissue Diseases (2) · Lung Diseases, Interstitial (2) · Pain (2) · Rare Diseases (2) · Raynaud Disease (2) · Aortic Arch Syndromes (1) · Arthritis, Rheumatoid (1) · Behcet Syndrome (1) · Calcinosis (1) · Cholangitis, Sclerosing (1) · Colitis, Ulcerative (1) · Crohn Disease (1)
Skin Diseases (30) · Skin and Connective Tissue Diseases (30) · Connective Tissue Diseases (28) · Pathological Conditions, Signs and Symptoms (7) · Lung Diseases (5) · Pathologic Processes (5) · Respiratory Tract Diseases (5) · Cardiovascular Diseases (4) · Joint Diseases (4) · Musculoskeletal Diseases (4) · Vascular Diseases (4) · Signs and Symptoms (3) · Skin Diseases, Vascular (3) · Disease Attributes (2) · Embolism and Thrombosis (2)
Imatinib Mesylate (2) · Mycophenolic Acid (2) · treprostinil (2) · Antilymphocyte Serum (1) · Bortezomib (1) · Cognitive Behavioral Therapy (1) · Cyclophosphamide (1) · Fecal Microbiota Transplantation (1) · GLPG1690 (1) · Interleukin-2 (1) · Methotrexate (1) · Prednisolone (1) · Relaxin (1) · Rituximab (1) · SAR-100842 (1)
Hospital for Special Surgery, New York (3) · Assistance Publique - Hôpitaux de Paris (2) · Sanofi (2) · University of California, Los Angeles (2) · Active Biotech AB (1) · Boston University (1) · Fred Hutchinson Cancer Center (1) · Genentech, Inc. (1) · Genzyme, a Sanofi Company (1) · Gesynta Pharma AB (1) · Heidelberg University (1) · IRCCS San Raffaele (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Johns Hopkins University (1) · Lakefront Biotherapeutics NV (1)
United States (18) · United Kingdom (7) · Italy (5) · France (4) · Germany (4) · Belgium (3) · Canada (2) · Mexico (2) · Poland (2) · Switzerland (2) · Argentina (1) · Estonia (1) · Japan (1) · Netherlands (1) · Norway (1)
Robert Spiera, MD (3) · Anna-Maria Hoffmann-Vold, MD, PhD (1) · Ariane Herrick, MD (1) · Ayumi Yoshizaki, MD, PhD (1) · Carlos Hinojosa, MD (1) · Charlotte Edenius (1) · Daniel E. Furst, MD (1) · Dinesh Khanna, MD (1) · G. Scott Herron (1) · James Seibold, MD (1)
PMID 28298564, PMID 19950289, PMID 21398330, PMID 21769849, PMID 26283632, PMID 27370878, PMID 29073351, PMID 29732731, PMID 30277862, PMID 30472651, PMID 31655622, PMID 31858338, PMID 32963047, PMID 34168032, PMID 34330322, PMID 34718447, PMID 35894657, PMID 35943798, PMID 36637209, PMID 39900089
2019 (2), 2016 (1), 2018 (1), R01AR047219 (1), R34HL122558 (1)